Main Menu

A hybridoma cell line producing a monoclonal rat antibody specific to mouse Ly-6A/E (Sca-1) (clone D7) as described in J Immunol. 1986 Nov 15;137(10):3240-6 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD90 (Thy-1) (clone G7) as described in J Exp Med. 1984 Mar 1;159(3):716-30 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication.

Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.

Rotaviral infection is the most common gastrointestinal illness of children in the world, affecting both developed and developing economies. There is no specific drug treatment for rotavirus infection. Vaccination and good hygiene are key to prevention.

Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided):

1. PA.

Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 341): https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=152.

Expression, purification, and validation of anthrax toxin proteins.

Ccr9^-/- mice may be useful for studying the role of CCR9 in T lymphocyte development and migration.

Mice will be distributed by The Jackson Laboratory; details about this mouse strain (Stock No. 027041) may be found at https://www.jax.org/strain/027041.